Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. (Q48853473)

16 February 2018

title

Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. (English)

1 reference

16 February 2018

0 references

1 reference

2

1 reference

16 February 2018

Andrea Danese

3

1 reference

16 February 2018

Peter B. Jones

12

1 reference

16 February 2018

Robin Murray

14

1 reference

16 February 2018

Kevin Morgan

Kevin D Morgan

4

0 references

Carmine Pariante

Carmine M Pariante

1

0 references

Craig Morgan

Craig Morgan

6

0 references

Christos Pantelis

10

Christos Pantelis

1 reference

16 February 2018

Gerard Hutchinson

9

Gerard Hutchinson

1 reference

16 February 2018

Dennis Velakoulis

11

Dennis Velakoulis

1 reference

16 February 2018

author name string

Flora Brudaglio

5

1 reference

16 February 2018

Paul Fearon

7

1 reference

16 February 2018

Ken Orr

8

1 reference

16 February 2018

Julian Leff

13

1 reference

16 February 2018

language of work or name

English

0 references

publication date

1 October 2005

1 reference

16 February 2018

published in

Neuropsychopharmacology

1 reference

16 February 2018

volume

30

1 reference

16 February 2018

issue

10

1 reference

16 February 2018

page(s)

1923-1931

1 reference

16 February 2018

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300766

exact match

0 references

cites work

Causal association between cannabis and psychosis: examination of the evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Incidence of schizophrenia in south-east London between 1965 and 1997

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Normal pituitary volumes in children and adolescents with bipolar disorder: a magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Stress and the progression of the developmental hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Modern imaging of the pituitary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Estradiol levels in psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Pituitary size in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Corticotroph cell hyperplasia in a patient with addison disease: Case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

In vivo assessment of pituitary gland volume with magnetic resonance imaging: the effect of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Emotional reactivity to daily life stress in psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Depression, Stress and the Adrenal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

A novel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Pituitary volume in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Prolactin release, oestrogens and proliferation of prolactin-secreting cells in the anterior pituitary gland of adult male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Psychoendocrinology of Ego Disintegration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Neighbourhood variation in incidence of schizophrenia. Evidence for person-environment interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Quantification of morphological changes in pituitary corticotropes produced by in vivo corticotropin-releasing factor stimulation and adrenalectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

Life events and psychosis. Initial results from the Camberwell Collaborative Psychosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

7 January 2021

Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

7 January 2021

Stress and the genesis of diabetes mellitus in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

7 January 2021

Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

7 January 2021

Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

7 January 2021

MRI study of the pituitary gland in adolescent depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

7 January 2021

Pituitary enlargement associated with Addison's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

7 January 2021

Decreased pituitary volume in patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

7 January 2021

Lower prolactin bioactivity in unmedicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300766

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300766

1 reference

16 February 2018

1 reference

16 February 2018